v3.26.3
Interests in Other Entities - Schedule of Summarized Statement of Comprehensive Loss (Details) - USD ($)
12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2024
Schedule of Summarized Statement of Comprehensive Loss [Line Items]      
Loss for the year $ (56,950,494) $ (38,342,457) $ (47,949,119)
Total comprehensive loss (56,329,054) (37,878,423) (47,746,163)
Loss allocated to non-controlling interests (1,801,344) (1,639,368) $ (1,964,213)
Radiopharm Ventures LLC [Member]      
Schedule of Summarized Statement of Comprehensive Loss [Line Items]      
Loss for the year (11,227,807) (6,110,449)  
Total comprehensive loss (11,227,807) (6,110,449)  
Loss allocated to non-controlling interests $ (1,801,344) $ (1,639.368)